Mikhail Blagosklonny earned his MD in Internal Medicine and his PhD in Experimental Medicine and Cardiology at the First Pavlov State Medical University in St. Petersburg. In 2002, Mikhail became an associate professor of medicine at New York Medical College in Valhalla, New York.
Presently, Mikhail Blagosklonny is an Oncology Professor at Roswell Park Cancer Institute. His research includes anti-aging drugs, cancer therapies, and Biogerontology, or the underlying mechanisms of aging. His research includes cellular and molecular biology and clinical investigations. He studies tumor suppressors, mitosis, the cell cycle, anticancer therapeutics, apoptosis, and drug resistance for normal cells.
He is also the editor-in-chief of Oncotarget and Cell Cycle. Mikhail has proposed the hypothesis for the potential role of TOR Signaling in cancer and aging. To counteract lie extension, Mikhail proposed using a popular cancer treatment drug called Rapamycin. Mikhail has done extensive research and believes Rapamycin to be an anti-aging drug that will improve immunity and end aging. With proper doses and schedules, Rapamycin can extend the life span. View Mikhail’s profile on Google Scholar
Originally proposed in 2008, Mikhail’s Rapamycin hypothesis received a lot of criticism. But by 2014, the medical world now takes the TOR-centric model for granted.
Rapamycin is also safe enough to give to transplant patients for years on a daily basis. It has been used to treat cancer and autoimmune disease and research suggests that Rapamycin can also treat osteoporosis and Alzheimer’s.
Mikhail Blagosklonny has done a huge amount of research about Rapamycin, and is a proponent of using this non-toxic drug to help fight aging and the terrible degenerative diseases that goes along with it, like Alzheimer’s and dementia. He believes aging and cancer can be cured and his optimism has fueled his research to help him find new, groundbreaking discoveries that will change the medical world forever and help people live longer, healthier, and happier lives.
He warns that Rapamycin is not an elixir for immortality. Even after many of the current diseases and causes of death related to aging are wiped out, new, unknown diseases will appear. He calls this post-aging syndrome. However, Rapamycin will still allow people to live longer, happier lives without degenerative diseases damaging their lifestyles.
His determination, drive, and commitment to finding a cure for cancer has helped him become one of the biggest oncology researchers in the world. Visit classroomvoices.org to read more about Mikhail.